Participating in a clinical trial for multiple myeloma, which is particularly difficult to diagnose, typically places a heavy burden on patients. Patients often visit multiple doctors before learning the cause of their condition, then undergo a series of invasive tests such as bone marrow biopsy and genome sequencing. Conducting clinical trials requires a deep understanding of patient characteristics and current treatment patterns for insight on the patient journey.
These trials are complicated by the need for specialized sites with expertise in hematologic malignancies and the logistics of collection, manufacturing, and delivery of cell therapies. Further, they must be able to manage large volumes of biomarker, safety, and efficacy data.
Experience in the past 5 years in Multiple Myeloma
+
clinical projects
+
sites
+